[{"address1": "18 Campus Boulevard", "address2": "Suite 100", "city": "Newtown Square", "state": "PA", "zip": "19073", "country": "United States", "phone": "628-277-4836", "website": "https://www.arrivent.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Dr. Zhengbin  Yao Ph.D.", "age": 57, "title": "Co-Founder, Chairman, President & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 791089, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stuart  Lutzker M.D., Ph.D.", "age": 62, "title": "Co-Founder, President of Research & Development and Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 709426, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Robin  LaChapelle M.A.", "age": 50, "title": "Co-Founder & COO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 586453, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Winston  Kung M.B.A.", "age": 47, "title": "CFO & Treasurer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yang  Wang Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James Paul Kastenmayer J.D., Ph.D.", "age": 51, "title": "General Counsel & Secretary", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dandan  Dong", "age": 38, "title": "Chief Business Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Meghna  Chowdary", "title": "Senior Vice President of Commercial Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 26.12, "open": 25.6, "dayLow": 25.195, "dayHigh": 26.7, "regularMarketPreviousClose": 26.12, "regularMarketOpen": 25.6, "regularMarketDayLow": 25.195, "regularMarketDayHigh": 26.7, "forwardPE": -10.037736, "volume": 269867, "regularMarketVolume": 269867, "averageVolume": 103593, "averageVolume10days": 261250, "averageDailyVolume10Day": 261250, "bid": 26.49, "ask": 26.61, "bidSize": 300, "askSize": 300, "marketCap": 893384960, "fiftyTwoWeekLow": 14.35, "fiftyTwoWeekHigh": 28.65, "fiftyDayAverage": 21.6042, "twoHundredDayAverage": 19.743725, "currency": "USD", "enterpriseValue": 578844544, "floatShares": 16673381, "sharesOutstanding": 33585900, "sharesShort": 1632418, "sharesShortPriorMonth": 1620811, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.048600003, "heldPercentInsiders": 0.13643, "heldPercentInstitutions": 0.64792997, "shortRatio": 26.34, "shortPercentOfFloat": 0.0673, "impliedSharesOutstanding": 33585900, "bookValue": 8.853, "priceToBook": 3.0046313, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -74885000, "trailingEps": -2.24, "forwardEps": -2.65, "52WeekChange": 0.306, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AVBP", "underlyingSymbol": "AVBP", "shortName": "ArriVent BioPharma, Inc.", "longName": "ArriVent BioPharma, Inc.", "firstTradeDateEpochUtc": 1706279400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dc868aa9-99a9-3d14-9b09-40806adb643e", "messageBoardId": "finmb_1671738162", "gmtOffSetMilliseconds": -14400000, "currentPrice": 26.6, "targetHighPrice": 35.0, "targetLowPrice": 28.0, "targetMeanPrice": 31.83, "targetMedianPrice": 31.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 298668992, "totalCashPerShare": 8.893, "totalDebt": 250000, "quickRatio": 24.749, "currentRatio": 25.501, "debtToEquity": 0.084, "returnOnAssets": -0.21224001, "returnOnEquity": -0.31028, "freeCashflow": -46733124, "operatingCashflow": -68070000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]